Prometrium Missed-Dose Protocol: What to Do When You Skip Micronized Progesterone

Direct answer

If you miss one dose of Prometrium, take it as soon as you remember that same day. If it is close to the time of your next scheduled dose, skip the missed one and resume your normal schedule. This is the instruction in the FDA-approved prescribing information, not a HealthRX.com recommendation (FDA label, Prometrium capsules). Never take two doses together to make up for a missed one. A single missed dose in a 12-day cyclic regimen is not expected to meaningfully change endometrial protection. Missing two or more consecutive doses in a cyclic course, or several consecutive nights on a continuous regimen, is the point at which you should contact your prescriber rather than self-manage, because the degree of risk from a specific gap has not been quantified in a way that supports a confident, individualized answer here.

What Prometrium is and how it fits into hormone therapy

Prometrium is the brand name for oral micronized progesterone, a bioidentical form of progesterone suspended in peanut oil to improve gut absorption. It is distinct from synthetic progestins such as medroxyprogesterone acetate (Provera) and norethindrone acetate, which are different molecules with different receptor binding and half-lives. Micronized progesterone is FDA-approved for two indications: treatment of secondary amenorrhea, and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens without a hysterectomy. Vaginal formulations of micronized progesterone (such as Crinone or Endometrin) are separate products with separate dosing and are not interchangeable with the oral capsule discussed here.

Progesterone binds nuclear progesterone receptors in the endometrial lining and converts estrogen-stimulated proliferative tissue into a secretory state. This secretory transformation is the biological basis for endometrial protection during estrogen therapy. Oral progesterone also undergoes substantial liver metabolism into neuroactive metabolites, including allopregnanolone, which acts on GABA-A receptors and produces sedation. This is why prescribers commonly direct bedtime dosing: the drowsiness is an expected pharmacologic effect, not an unrelated side effect to work around.

Evidence anchor: the FDA-approved label is the primary source for the missed-dose instruction, the dosing regimens, and the peanut-oil contraindication. Statements about comparative trial outcomes (progestin type and lipid effects, breast cancer risk by progestogen type, minimum days of exposure needed for protection) come from the older hormone-therapy trial literature and observational cohorts. Those specific studies are referenced by name below, but the exact citations could not be verified against the primary literature for this draft and should be checked before publication.

Standard dosing regimens

Cyclic regimen: 200 mg taken orally at bedtime for 12 consecutive days each cycle, paired with estrogen on a fixed schedule. This is the regimen specified in the FDA-approved label for endometrial protection when combined with conjugated estrogens (FDA label). It typically produces a withdrawal bleed near the end of the progesterone-free interval.

Continuous-combined regimen: 100 mg taken nightly without a break, alongside daily estrogen. This pattern is common in clinical practice, particularly for women further from menopause who want to avoid a monthly bleed, but it is an off-label use for endometrial protection built on clinical experience and observational practice rather than the pivotal trial data behind the cyclic regimen. Patients should understand this distinction rather than assume both regimens carry equal trial-level support.

What the FDA label says about a missed dose

The prescribing information instructs patients who miss a dose to take it as soon as remembered, and to skip it if it is almost time for the next dose, without doubling up (FDA label). Below is how that instruction plays out in the two common scenarios readers ask about.

Remembered later the same day: take the capsule when you remember. Expect drowsiness within roughly one to a few hours, consistent with the allopregnanolone-mediated sedation described above. If you need to drive or work shortly after, it may be reasonable to wait and simply accept the one missed dose rather than take it at an inconvenient time, but that is a judgment call to make with your prescriber, not a substitute for their guidance.

Close to the next scheduled dose: skip the missed dose. Taking two doses close together increases peak drug and metabolite levels and raises the likelihood of pronounced sedation, dizziness, or next-day grogginess.

Never double the dose. This is the explicit label instruction and is not open to individual interpretation.

Why consecutive missed doses matter more than a single miss

Estrogen alone stimulates proliferation of the endometrial lining. Progesterone opposes that proliferation and converts the tissue to a secretory state, which is the mechanism thought to prevent hyperplasia. The pivotal trial supporting the cyclic 200 mg x 12-day regimen (the PEPI trial, a multicenter randomized trial of postmenopausal hormone regimens published in JAMA in 1995) is widely cited as showing that adequate days of progestogen exposure per cycle, rather than the peak blood level on any single day, is what correlates with endometrial protection. We are not able to verify the exact hyperplasia rates attributed to that trial in earlier drafts of this article from the source material provided, and any specific percentage should be confirmed against the original publication before it is republished as fact.

What is more defensible as a general statement: hormone therapy guidelines and consensus statements from bodies such as the Endocrine Society and international menopause societies describe a minimum duration of progestogen exposure per cycle as necessary for endometrial protection, generally discussed in the range of about 10 to 12 days per month for cyclic regimens. Falling meaningfully short of that duration, because of multiple missed doses, is the scenario that should prompt clinical follow-up rather than self-managed catch-up dosing.

For continuous 100 mg dosing, a single missed night is a brief gap in an otherwise unbroken regimen. Several consecutive missed nights, while continuing daily estrogen, creates a longer period of unopposed estrogen exposure. The point at which unopposed estrogen begins to matter clinically depends on individual factors (years since menopause, endometrial thickness, other risk factors) that this article cannot assess for you.

Absorption: timing and food matter, even when you don't miss a dose

The FDA label notes that taking the capsule with food increases absorption compared with taking it fasting. In practice, this means a "catch-up" dose taken the next morning on an empty stomach may be absorbed less completely than your usual bedtime dose taken after dinner. That is not a reason to skip the catch-up dose; taking it under the label's missed-dose rule is still the correct step. It is a reason not to assume a made-up dose is pharmacologically identical to an on-schedule one, and it may partly explain why some patients notice spotting after resuming a missed cycle.

Prometrium compared with synthetic progestins on the missed-dose question

Synthetic progestins such as medroxyprogesterone acetate and norethindrone acetate generally have different half-lives and receptor binding profiles than micronized progesterone, and clinicians sometimes describe them as more forgiving of a single missed dose because of higher receptor affinity. Observational literature (notably the French E3N cohort) has reported differences in breast cancer risk associated with micronized progesterone compared with synthetic progestins when combined with estrogen, which is one reason micronized progesterone is often preferred for hormone therapy despite requiring more consistent daily dosing. These are observational associations, not randomized trial evidence of causation, and should be described to patients with that caveat. The exact risk ratios cited in earlier versions of hormone-therapy articles on this topic could not be verified here and need primary-source confirmation before republication.

Peanut allergy and other reasons to avoid this formulation

Prometrium capsules are formulated in peanut oil and are contraindicated in patients with peanut hypersensitivity, per the FDA label (FDA label). Patients with a peanut allergy should not take this specific oral formulation; vaginal micronized progesterone products or synthetic progestins are alternatives to discuss with a prescriber. This is a labeled contraindication, not a suggestion.

Can a blood test tell you whether a missed dose mattered?

A single serum progesterone level drawn after a missed dose is not a reliable way to judge endometrial protection. Oral micronized progesterone produces variable peak blood levels between individuals and between doses depending on food intake and timing, and no single trough measurement has been established as predictive of endometrial response. What correlates with protection, based on the trial evidence behind the cyclic regimen, is cumulative days of exposure across the cycle, not a snapshot blood level. If a prescriber is concerned about endometrial adequacy after repeated missed doses, the appropriate next step is a clinical evaluation such as transvaginal ultrasound measurement of endometrial thickness or endometrial biopsy, not a home blood draw.

Evidence boundary: what is established, what is plausible, what is not

Established by the FDA label: the missed-dose instruction (take when remembered, skip if close to next dose, never double), the cyclic 200 mg x 12-day regimen for FDA-approved endometrial protection when combined with conjugated estrogens, the peanut oil contraindication, and the general food effect on absorption.

Plausible but not established with a precise number in this draft: the exact number of consecutive missed doses that meaningfully raises endometrial hyperplasia risk in a given patient; the exact percentage difference in hyperplasia rates between adequately dosed and under-dosed cycles; exact peak plasma concentration ranges after a dose taken with versus without food.

Not established as a general rule: that the 100 mg continuous regimen provides equivalent endometrial protection to the FDA-approved 200 mg cyclic regimen when doses are missed. That comparison has not been demonstrated in the trial evidence available for this article and should not be assumed by patients using the continuous regimen.

Individual risk after a missed dose depends on cycle timing, years since menopause, endometrial thickness, and other health factors that only a prescriber who knows the patient's history can weigh. Nothing here is a substitute for that individualized assessment.

Clinician conversation and monitoring framework for missed Prometrium doses

Use this as a structured way to bring a missed-dose situation to a prescriber, not as a self-management protocol.

Checkpoint 1: How many doses were missed, and in which regimen?

• Cyclic (200 mg x 12 days): count how many of the 12 scheduled days were actually taken.
• Continuous (100 mg nightly): count consecutive missed nights.
• Bring this count to the conversation; "I think I missed a couple" is less useful than "I missed days 4 and 5 of a 12-day cycle."

Checkpoint 2: Was the missed-dose label instruction followed?

• Confirm whether the missed dose was taken same-day, skipped because it was near the next dose, or accidentally doubled.
• If doubling occurred, mention any sedation, dizziness, or unusual symptoms that followed, since this affects how the prescriber interprets the episode.

Checkpoint 3: Any bleeding or spotting since the missed dose(s)?

• New spotting or bleeding after a missed dose is a clinically relevant symptom to report, not something to wait out, because it may reflect incomplete endometrial suppression.

Checkpoint 4: Where are you in relation to the FDA-established minimum exposure window?

• On a cyclic regimen, ask specifically whether the number of progesterone-covered days this cycle is likely sufficient, or whether the prescriber wants to extend, restart, or monitor the current cycle.
• This is a judgment call for the prescriber based on trial-derived duration thresholds, not something a patient can determine alone from a label insert.

Stop-and-call conditions (do not wait for a routine visit):

• Two or more consecutive missed doses in a cyclic regimen.
• Three or more consecutive missed nights on continuous dosing.
• Any new or unexpected vaginal bleeding after a missed dose or doses.
• Uncertainty about whether to resume mid-cycle, restart the cycle, or wait for the next one.

Situations that generally do not require an urgent call, but are still worth mentioning at the next routine visit:

• A single missed dose that was taken the next morning per the label instruction.
• A single skipped dose (too close to the next one) followed by normal resumption.
• One missed night on continuous dosing with no bleeding or other symptoms.

Where label guidance ends and individualized care begins: The FDA label covers the mechanics of a missed dose. It does not, and cannot, tell a specific patient whether her own endometrium, her time since menopause, her estrogen dose, or her personal bleeding pattern changes the risk calculus. That assessment requires her prescriber, and in some cases an ultrasound or biopsy, not a generic protocol.

Frequently asked questions

References

1. Prometrium (progesterone, USP) capsules, prescribing information. U.S. Food and Drug Administration

Other claims in this article referencing hormone-therapy trial and cohort literature (including the PEPI trial, guideline statements from professional societies, and progestogen comparison studies) are described in general terms because the specific citations inherited from the prior draft could not be verified against the primary literature. These should be confirmed against the original publications by a qualified reviewer before any specific statistic from them is republished.